tirzepatide phase 3 trial 80 weeks weight change The numbers from Lilly's retatrutide dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user tirzepatide phase 3 trial 80

Drucker commented: GLP1 [drugs] have given us so many wonderful results, but tackling these very challenging brain disorders has been disappointing There was a hope that we would see some benefit, and we didnt. From the Alzheimers Drug Discovery Foundation (ADDF), Howard Fillit, MD, emphasized that even negative trials move the field forward, pointing to the need to target the broader pathobiology of Alzheimers and to consider preventive or combination approaches informed by biomarker profiles

We look forward to this product offering a new therapeutic experience for more patients with end-stage renal disease (ESRD)

In this context, GLP-1 agonists represent a potentially valuable tool within a multimodal treatment approach, particularly for patients who have not achieved adequate weight loss through lifestyle modification alone

Normal weight fluctuations from hydration, sodium intake, hormonal cycles, and digestive timing can swing several pounds in either direction

Drink cold water

Drucker hinted at early promising results for patients with metabolic liver disease and noted ongoing studies exploring GLP-1's effects on Alzheimer's disease, with results expected soon